FAILED
首站-论文投稿智能助手
典型文献
Mucosal vaccine delivery:A focus on the breakthrough of specific barriers
文献摘要:
Mucosal vaccines can effectively induce an immune response at the mucosal site and form the first line of defense against microbial invasion.The induced mucosal immunity includes the proliferation of effector T cells and the production of IgG and IgA antibodies,thereby effectively blocking microbial infection and transmission.However,after a long period of development,the transformation of mucosal vaccines into clin-ical use is still relatively slow.To date,fewer than ten mucosal vaccines have been approved.Only seven mucosal vaccines against coronavirus disease 2019(COVID-19)are under investigation in clinical trials.A representative vaccine is the adenovirus type-5 vectored COVID-19 vaccine(Ad5-nCoV)developed by Chen and coworkers,which is currently in phase III clinical trials.The reason for the limited progress of mucosal vaccines may be the complicated mucosal barriers.Therefore,this review summarizes the characteristics of mucosal barriers and highlights strategies to overcome these barriers for effective mucosal vaccine delivery.
文献关键词:
作者姓名:
Mengwen Huang;Miaomiao Zhang;Hongbin Zhu;Xiaojiao Du;Jun Wang
作者机构:
School of Biomedical Sciences and Engineering,South China University of Technology,Guangzhou International Campus,Guangzhou 511442,China;National Engineering Research Center for Tissue Restoration and Reconstruction,South China University of Technology,Guangzhou 510006,China;Guangdong Provincial Key Laboratory of Biomedical Engineering,South China University of Technology,Guangzhou 510006,China;School of Medicine,South China University of Technology,Guangzhou 510006,China;Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education,South China University of Technology,Guangzhou 510006,China
引用格式:
[1]Mengwen Huang;Miaomiao Zhang;Hongbin Zhu;Xiaojiao Du;Jun Wang-.Mucosal vaccine delivery:A focus on the breakthrough of specific barriers)[J].药学学报(英文版),2022(09):3456-3474
A类:
B类:
Mucosal,delivery,focus,breakthrough,specific,barriers,vaccines,can,effectively,immune,response,mucosal,site,first,line,defense,against,microbial,invasion,induced,immunity,includes,proliferation,effector,cells,production,IgG,IgA,antibodies,thereby,blocking,infection,transmission,However,after,long,period,development,transformation,into,use,still,relatively,slow,To,date,fewer,than,ten,have,been,approved,Only,seven,coronavirus,disease,are,under,investigation,clinical,trials,representative,adenovirus,type,vectored,Ad5,nCoV,developed,Chen,coworkers,which,currently,phase,III,reason,limited,progress,may,complicated,Therefore,this,review,summarizes,characteristics,highlights,strategies,overcome,these
AB值:
0.60172
相似文献
The complexation of insulin with sodium N-[8-(2-hydroxybenzoyl)amino]-caprylate for enhanced oral delivery:Effects of concentration,ratio,and pH
Huixian Weng;Lefei Hu;Lei Hu;Yihan Zhou;Aohua Wang;Ning Wang;Wenzhe Li;Chunliu Zhu;Shiyan Guo;Miaorong Yu;Yong Gan-School of Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210046,China;State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing 210023,China;Nano Science and Technology Institute,University of Science and Technology of China,Nanjing 215123,China;University of Chinese Academy of Sciences,Beijing 100049,China;NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients,National Institutes for Food and Drug Control,Beijing 100050,China
Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine
Qingrui Huang;Jiawei Zeng;Qingyun Lang;Feng Gao;Dejun Liu;Siyu Tian;Rui Shi;Ling Luo;Hao Wang;Liping Hu;Linrui Jiang;Yawei Liu;Kailiang Li;Yunbo Wu;Junjie Xu;Wenxi Jiang;Ning Guo;Zhihai Chen;Xiaohua Hao;Ronghua Jin;Jinghua Yan;Yufa Sun-CAS Key Laboratory of Pathogenic Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China;University of Chinese Academy of Sciences,Beijing 101408,China;College of Life Sciences,Anhui Agricultural University,Hefei 230036,China;Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China,Beijing 100017,China;Institute of Physical Science and Information,Anhui University,Hefei 230039,China;National Center for Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China
A live attenuated virus-based intranasal COVID-19 vaccine provides rapid,prolonged,and broad protection against SARS-CoV-2
Junyu Chen;Pui Wang;Lunzhi Yuan;Liang Zhang;Limin Zhang;Hui Zhao;Congjie Chen;Xijing Wang;Jinle Han;Yaode Chen;Jizong Jia;Zhen Lu;Junping Hong;Zicen Lu;Qian Wang;Rirong Chen;Ruoyao Qi;Jian Ma;Min Zhou;Huan Yu;Chunlan Zhuang;Xiaohui Liu;Qiangyuan Han;Guosong Wang;Yingying Su;Quan Yuan;Tong Cheng;Ting Wu;Xiangzhong Ye;Tianying Zhang;Changgui Li;Jun Zhang;Huachen Zhu;Yixin Chen;Honglin Chen;Ningshao Xia-State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,National Institute of Diagnostics and Vaccine Development in Infectious Diseases,School of Life Sciences,School of Public Health,Xiamen University,Xiamen 361102,China;State Key Laboratory of Emerging Infectious Diseases,School of Public Health,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Hong Kong 999077,China;National Institute for Food and Drug Control,Beijing 102629,China;Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.,Beijing 102206,China;Guangdong-Hong Kong Joint Laboratory of Emerging Infectious Diseases/Joint Laboratory for International Collaboration in Virology and Emerging Infectious Diseases,Joint Institute of Virology(STU/HKU),Shantou University,Shantou 515063,China;EKIH Pathogen Research Institute,Shenzhen 518067,China
Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
Mengjiao Li;Zi-Wei Ye;Kaiming Tang;Liang Guo;Wenwen Bi;Yuyuan Zhang;Yan-dong Tang;Guoguang Rong;Mohamad Sawan;Xin Yin;Ren Sun;Shuofeng Yuan;Bobo Dang-Fudan University,Shanghai,China;Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China;Center for Infectious Disease Research,Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou,Zhejiang,China;Institute of Biology,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Emerging Infectious Diseases,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Veterinary Biotechnology,Harbin Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Harbin,China;CenBRAIN Lab.,School of Engineering,Westlake University,Hangzhou,Zhejiang,China;CenBRAIN Lab.,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;School of Biomedical Sciences,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
Yuqi Zhu;Xinyi Yang;Jingna Xun;Jun Liu;Qing Wen;Yixiao Lin;Xiaoting Shen;Jun Chen;Songhua Yuan;Xiaying Zhao;Jing Wang;Hanyu Pan;Jinlong Yang;Zhiming Liang;Yue Liang;Qinru Lin;Huitong Liang;Min Li;Jianping Liu;Yinzhong Shen;Xiaoyan Zhang;Pengfei Wang;Daru Lu;Chunhua Yin;Jianqing Xu;Shibo Jiang;Hongzhou Lu;Huanzhang Zhu-State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology,Ministry of Education,Institute of Genetics,School of Life Sciences,Fudan University,Shanghai,200438,China;Scientific Research Center,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Fubio(Suzhou)Biomedical Technology Co.,Ltd,Suzou,215300,China;Department of Infectious Diseases and Immunology,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Fudan University,Shanghai,200032,China;Department of Infectious Diseases and Nursing Research Institution,National Clinical Research Center for Infectious Diseases,The Third People's Hospital of Shenzhen,Shenzhen,518112,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。